Presentation (CTI)

OBJECTIVES: Which dataset, frozen at which moment, will actually be assessed? Modern trials evolve: data cut-offs shift and estimand frameworks (ICH E9(R1)) reframe the very question being answered. This study examined whether the JCA framework provides sufficient procedural clarity on data cut-offs, post-submission evidence updates, and estimand application.
METHODS: A policy and methodological review was conducted using the HTAR, implementing regulations, ICH E9(R1), and guidance relating to evidence generation and clinical trial interpretation. The analysis focused on three operational domains: temporal definition of evidence packages, treatment of post-submission data updates, and integration of estimand concepts into HTA assessment practice.
RESULTS: The review identified significant procedural ambiguity. Neither the Regulation nor implementing instruments provide detailed rules regarding the selection of assessment data cut-offs or the admissibility of post-submission evidence updates. Simultaneously, elements of estimand terminology appear increasingly within assessment discussions despite the absence of a formally adopted methodological framework governing their application. This creates uncertainty regarding which evidence version will ultimately be assessed and how treatment-policy, hypothetical, or other estimands will influence conclusions. Manufacturers face difficulty anticipating evidentiary expectations, while external observers may struggle to reconstruct the analytical standards applied in individual assessments.
CONCLUSIONS: Without explicit rules, the evidentiary target keeps moving and conclusions become hard to reproduce. Clear policies on data cut-offs, evidence updates, and estimand use would give developers a stable target and make assessments auditable.